Icône BioRender

Cancer cell (HeLa line)

Cancer cell (HeLa line) - Editable icon of A triangular HeLa cancer cell with thin projections.
[{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64e/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64e/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64d/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64d/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64c/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64c/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64b/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64b/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64a/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64a/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f649/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f649/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f648/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f648/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f647/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f647/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f646/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f646/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f645/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f645/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f644/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f644/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f643/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f643/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f642/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f642/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f641/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f641/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f640/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f640/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63f/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63f/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63e/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63e/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63d/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63d/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63c/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63c/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63b/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63b/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63a/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63a/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f639/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f639/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f638/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f638/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f637/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f637/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f636/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f636/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f635/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f635/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f634/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f634/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f633/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f633/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f632/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f632/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f631/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f631/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f630/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f630/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62f/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62f/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62e/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62e/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62d/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62d/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62c/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62c/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62b/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62b/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62a/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62a/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f629/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f629/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f628/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f628/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f627/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f627/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f626/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f626/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f625/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f625/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f624/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f624/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f623/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f623/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f622/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f622/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f621/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f621/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f620/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f620/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f61f/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f61f/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f61e/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f61e/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f61d/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f61d/60ba4188d6c9560027a6f61c.png"}]
Utiliser cette icône – Gratuit
Aucune carte de crédit requise pour l'inscription.

Cette icône est entièrement modifiable dans BioRender

  • Ajoutez du texte, des formes et d'autres icônes
  • Recherchez parmi plus de 50 000 icônes scientifiquement exactes
  • Changez les couleurs et réorganisez chaque icône, ligne et étiquette
  • Exportez ou partagez pour tout type d'utilisation
Scientist Avatars

Rejoignez plus de 4 millions de scientifiques qui créent déjà des figures prêtes à être publiées

Passez des icônes à la figure terminée – en quelques minutes

  • Rechercher à partir de plus de 50 000 icônes scientifiquement exactes et évaluées par des pairs
  • Personnalisez avec des étiquettes, des formes et des icônes supplémentaires – tout est entièrement modifiable
  • Exporter ou partagez vos figures avec vos collaborateurs
    ‍

Ce n'est pas tout à fait l'icône qu'il vous faut ? Découvrez-en plus.

Recherchez parmi plus de 50 000 icônes dans plus de 30 domaines des sciences de la vie.

search icon
arrow-right
HeLa,HeLa cell,cancer cell,immortal,cell line,cell clone,durable,prolific,cancer research,cancer study,virus research,genetics,Henrietta Lacks,Lacks,cervical cancer cells,hela
Voir plus

Essayez un synonyme, ou inscrivez-vous pour demander une icône depuis l'application.

Types d'images

Cancer cell (HeLa line) icon JPEG

Cancer cell (HeLa line) icon PNG

Cancer cell (HeLa line) icon SVG

Cancer cell (HeLa line) icon GIF

FAQ sur les icônes BioRender

How are scientists using the Cancer cell (HeLa line) icon in their work?

BioRender users often use the Cancer cell (HeLa line) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

Puis-je utiliser cette icône dans une figure ou une illustration scientifique BioRender ?

Yes, the Cancer cell (HeLa line) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Cancer cell (HeLa line) icon customizable in BioRender?

Most icons in BioRender, including the Cancer cell (HeLa line) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Cancer cell (HeLa line) icon for publication or presentations?

Yes, figures containing the Cancer cell (HeLa line) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Cancer cell (HeLa line) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Cancer cell (HeLa line) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

Qu'est-ce que BioRender ?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Cancer cell (HeLa line) icon along with our library of more than 30,000 life science icons.

Utiliser cette icône dans BioRender

Créez dès aujourd'hui des illustrations scientifiques professionnelles
antibody elements3D Phospholipid illustration

Vous recherchez du contenu scientifique ?

Parcourez plus de 50 000 icônes et modèles validés par des pairs, faciles à utiliser et gratuits.

Trouvez le vôtre dès maintenant
x icon